Maria Alevizopoulou

Mrs. Maria Alevizopoulou

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2026 in Biosensors
Verified
Journal Article
Open access
PDF file
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
GAGeorgios Anastasiou
Georgios Anastasiou
Iakovos KritikosIakovos Kritikos
Iakovos Kritikos
MAMaria Alevizopoulou
Maria Alevizopoulou
GAGeorgios Ar Alevizopoulos
Georgios Ar Alevizopoulos
Psychosis presents significant treatment challenges, and standard Cognitive Behavioral Therapy for psychosis often faces limitations due to patient engagement issues and reliance on subjective self-reporting. The integration of Virtual Reality (VR), physiological biosensors, and artificial intelligence offers a transformative opportunity to address these challenges. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. A thorough literature search was performed across seven databases. Twelve randomized controlled trials involving 1504 participants were included to assess VR-assisted CBT, VR treatment, and AVATAR therapy. Meta-analyses showed that VR interventions significantly decreased auditory verbal hallucinations (pooled SMD = −0.24, p = 0.0011) and paranoid thoughts (SMD = −0.26, p < 0.0001) compared to control conditions. This review supports integrating multi-modal biosensors to collect real-time, objective physiological data. Such integration enables the development of AI-driven, closed-loop systems that dynamically adjust the virtual environment based on the patient’s physiological state. VR-assisted therapies effectively reduce positive symptoms of psychosis. Incorporating biosensors is a crucial step toward a data-driven approach for personalized, closed-loop psychiatric care. Future efforts should focus on large-scale clinical trials, biomarker validation, and robust ethical frameworks to ensure safe and effective implementation.

22 September 2026 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
AAAristomenis G. Alevizopoulos
Aristomenis G. Alevizopoulos
VVVasileios Vasilakos
Vasileios Vasilakos
Iakovos KritikosIakovos Kritikos
Iakovos Kritikos
MAMaria Alevizopoulou
Maria Alevizopoulou
EKEleni Korompoki
Eleni Korompoki
SPStavroula A. Paschou
Stavroula A. Paschou
Background: Alcohol use disorder (AUD) affects millions worldwide, but current treatments, such as disulfiram, naltrexone, acamprosate, and topiramate, have limitations in efficacy and tolerability. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity, may offer a new approach by targeting brain pathways involved in alcohol cravings. Objectives: This review aims to systematically evaluate the preliminary efficacy and safety of GLP-1 RAs and other incretin-based therapies in treating AUD within a recent comparative context, alongside standard pharmacotherapies. Design: Systematic review. Data sources and methods: A comprehensive literature review was conducted by searching the PubMed/Medline, Web of Science, and Scopus databases from February through June 2025. The studies included were either randomized controlled trials (RCTs) or observational studies, written in English. Studies were selected based on their evaluation of GLP-1 RAs or comparator drugs in reducing alcohol consumption or related outcomes in patients with AUD. Results: The selected 12 studies correspond to a population of 95,004 participants, but only 663 were from RCTs, while the majority were from a single registry cohort. Emerging data suggest GLP-1 RAs may reduce heavy drinking days, particularly in individuals with a higher BMI. Furthermore, observational analyses indicate a potential association between GLP-1 RA use and reduced alcohol-related hospitalizations, while metabolic data suggest biologically plausible, albeit unconfirmed, hepatoprotective effects. Conclusion: While the large, aggregated sample size highlights the therapeutic promise of GLP-1 RAs for AUD, particularly for patients with metabolic comorbidities, the heavy reliance on observational data precludes claims of clinical equivalence with established pharmacotherapies. Appropriately powered, dedicated RCTs are required to confirm direct efficacy and long-term safety. Trial registration: Not registered.